Therapeutic modulation of immune checkpoints| Volume 51, SUPPLEMENT 1, S4, March 2015

Download started.


ITOC2 – 010. Virotherapy overcomes tumour resistance to PD1-immunotherapy by broad mutanome-directed T cell responses

      This paper is only available as a PDF. To read, Please Download here.
      Preexisting antitumoural T cell responses appear to be a precondition for effective PD1 immunotherapy, but concomitant cancer vaccinations did not affect the clinical outcome. We investigated whether oncolytic virotherapy (OV) is capable to overcome resistance to PD1-immunotherapy. To analyse antitumoural T cell responses, we performed transcriptome sequencing of PD1-resistant murine CMT64 cells and screened for putative neoepitopes in mutated genes using an MHC class I epitope prediction algorithm. Neoepitopes were then analysed by ELISpot analysis. Furthermore, induction of cytotoxic responses were confirmed by in vivo cytotoxic assays. Mutanome-specific T cells were detected by pentamers. PD1 immunotherapy was capable of inducing a single neoepitope-specific response, whereas OV elicited cytotoxic T cell responses to a conserved set of 5–7 neoepitopes. Unexpectedly, OV-induced antitumoural responses were not enhanced by subsequent PD1 blockade. Instead, we observed a broadening of T cell responses to additional neoepitopes of the mutanome. OV of the primary tumour abrogated tumour-specific resistance to PD1 immunotherapy as shown by improved elimination of disseminated lung colonies. Our observation was additionally confirmed in a transgenic cholangiocarcinoma model, where this approach completely eliminated lung metastasis. Our results strongly recommend viral oncolysis and concomitant PD1 immunotherapy for further evaluation in clinical studies.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect